1109 results about "Fibrosis" patented technology

Disclosed herein are antibodies that specifically bind to Gal3 and methods of use thereof. In some embodiments, also described herein are methods of inducing immune activation or promoting T cell or Natural Killer cell proliferation with an antibody that specifically binds to Gal3. Also disclosed herein are methods and compositions of reducing fibrosis or propensity thereof in a tissue with antibodies that specifically bind to Gal3. In some cases, the anti-Gal3 antibody also disrupts the interaction between Gal3 and TIM-3.

Aspects of the application provide anti-hemojuvelin antibodies and methods of using the same in treating myelofibrosis and / or conditions associated with myelofibrosis.

Disclosed herein are apparatuses, systems, kits, and methods for treating skin, such as skin tightening or for treating diseases, disorders, and conditions that would benefit from tissue area or volume reduction, skin restoration, skin tightening, skin lifting, and / or skin repositioning and / or for generally improving skin function or appearance (e.g., the removal of unwanted skin features or irregularities such as sebaceous glands, sweat glands, hair follicles, necrosis, and fibrosis). Such apparatuses, systems, kits, and methods comprise an apparatus having a handheld main body and a detachably attachable tip comprising one or more needles.

The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and / or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).

Modular mucosal tissue bioreactors combined with bioartificial mucus provide a high-fidelity, medium-throughput platform for evaluating CF treatments and modeling host-pathogen biology, a stepping stone towards better options for HEMT-nonresponsive patients. Whole lung ex vivo Cystic Fibrosis model system allows for investigation of candidate CF therapies.

The invention belongs to the technical field of medicines, and discloses an application of a Necrosulfenamide (NSA) compound in preparation of a medicine for resisting glaucoma trabecular network fibrosis. The NSA can inhibit abnormal activation of necroptosis-related pathways and significantly down-regulate fibrosis key factors, so that the structure and function of trabecular meshwork tissues are improved, and the aqueous humor outflow capacity is recovered. It is found for the first time that NSA not only has a stable and lasting intraocular pressure lowering effect, but also can reduce retinal ganglion cell damage in an intraocular hypertension state, and has definite treatment and protection effects on non-acute glaucoma and intraocular hypertension. The regulation effect of NSA on trabecular meshwork fibrosis is not disclosed in the prior art, the research blank in the field is filled, and a new pharmacological target and a clinical application strategy are provided for prevention and treatment of glaucoma and related intraocular hypertension diseases.

The present disclosure provides methods of treating pulmonary fibrosis, the methods comprising administering taladegib to a subject in need thereof.

The invention belongs to the technical field of biomedical materials and regenerative medicine, and relates to collagen-based injectable fiber hydrogel as well as a preparation method and application thereof. According to the injectable fiber hydrogel, methacrylated collagen and dithiothreitol are subjected to a thiol-ene click reaction rapidly under the action of a photoinitiator through illumination, a primary cross-linked network is formed, and the injection and in-situ gel forming requirements are met; then under the conditions that the pH is 6.5-8.0 and the temperature is 30-39 DEG C, collagen molecules are self-assembled into a nanofiber structure, and a bionic network similar to a natural extracellular matrix is obtained. The hydrogel disclosed by the invention has the advantages of rapid gelation, structural biomimetic property and biological activity; residual sulfydryl endows the hydrogel with active oxygen scavenging capacity, so that oxidative stress can be relieved, and immune response can be regulated; the fibrotic structure promotes cell adhesion, migration and tissue regeneration.

The present invention provides synthetic peptide compounds and uses thereof for therapy and diagnostics of complement-mediated diseases, such as inflammatory diseases, autoimmune diseases, and microbial and bacterial infections; and non-complement-mediated diseases, such cystic fibrosis and various acute diseases. The invention is directed to modifications of a synthetic peptide of 15 amino acids from the Polar Assortant (PA) peptide, which is a scrambled peptide derived from human Astrovirus protein. In some embodiments, the invention is directed to peptide compounds that are peptide mimetics, peptide analogs and / or synthetic derivatives of PA (e.g., sarcosine derivatives) having, for example, internal peptide substitutions, and modifications, including PEGylation at the N-terminus and C-terminus. The invention further provides methods of selecting at least one synthetic peptide for treating various conditions.

Provided herein are formulations for oral delivery or administration of therapeutic nucleic acids. An oral formulation can include: a nucleic acid; at least one casein protein; and a chitosan. In some embodiments, the formulations are liposome-free formulations having no cationic lipids typically used as transfection reagents in conventional nucleic acid formulations for oral delivery. The formulations provided herein find use in treating a condition associated with inflammation and / or fibrosis, or a cardiometabolic disorder by oral administration.

The present invention is in the fields of medicinal chemistry, biotechnology and pharmaceuticals. The invention provides compositions comprising one or more collagen mimetic peptides, optionally attached to one or more therapeutic compounds or one or more imaging compounds, for use in methods of treating, preventing, ameliorating, curing and diagnosing certain diseases and physical disorders in humans and veterinary animals, as well as methods of manufacturing such composition. The invention also provides medical devices comprising one or more such compositions of the invention. The invention also provides methods of use of such compositions and devices in treating and diagnosing certain diseases and physical disorders in humans and veterinary animals, including ocular diseases or disorders, skin diseases or disorders, certain cancers, particularly intraluminal cancers, gastrointestinal diseases or disorders, genitourinary tract diseases or disorders, fibrotic diseases / disorders and rheumatic diseases / disorders.

The present invention relates to pharmaceutical compositions containing N-(1,3-dimethylpyrazol-4-yl)sulfonyl-6-[3-(3,3, 3-trifluoro-2,2-dimethyl-propoxy)pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide, a solid dispersion of (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-7V-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-en indol-5-yl)cyclopropanecarboxamide, and a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxo-quinoline-3-carboxamide, including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical compositions.

The present disclosure provides methods of treating pulmonary fibrosis, the methods comprising administering taladegib to a subject in need thereof.

The invention belongs to the field of biological medicine, and particularly relates to application of urolithin D in preparation of medicine for relieving hyperuricemia. It is found for the first time that the urolithin D can significantly reduce the level of serum uric acid, improve the expression disorder of a kidney urate transporter, efficiently relieve or treat hyperuricemia and related diseases thereof, and relieve kidney injury and fibrosis; and the compound can be used for preparing medicines for treating hyperuricemia and related diseases, is low in cost and good in safety, and has a wide application prospect.

The invention discloses a composite amnion for improving contracture after tissue repair and a preparation method of the composite amnion. The composite membrane comprises a recombinant humanized collagen nanofiber membrane located in the middle layer and human decellularized amniotic membranes attached to the two faces of the nanofiber membrane. The composite membrane is prepared by preparing a recombinant humanized collagen nanofiber membrane through an electrostatic spinning technology and pressing the recombinant humanized collagen nanofiber membrane and a human decellularized amniotic membrane. The composite membrane has excellent mechanical properties and biological activity. Animal experiment results show that the composite film can effectively inhibit capsule contracture induced by radiotherapy, and the comprehensive effect of the composite film is obviously superior to that of a single-component material in the aspects of inflammation resistance, fibrosis resistance, degradation speed delaying, capsule compliance improving and the like. The composition can be used for improving the capsule contracture of the breast prosthesis, especially the capsule contracture induced by radiotherapy.

The invention discloses a mechanical response type engineered mesenchymal stem cell exosome preparation for treating diseases caused by fibrosis inflammation, a preparation method and application, and the exosome preparation is an exosome which is secreted by mesenchymal stem cells and has high cholesterol and high-efficacy protein. The exosome is prepared by culturing mesenchymal stem cells on a hydrogel matrix in a modulus hardness range of 1-50KPa, the exosome secretion amount of a single cell is (3-5) * 10 < 4 > / cell, the cholesterol content is (1-10) nM / 5mg exosome, and the size of the exosome is 110-140nm; the high-efficacy protein is a key functional protein for regulating and controlling the biological activity of the exosome and the cell action efficiency. The cholesterol content in the exosome is precisely regulated and controlled, the cytoplasm delivery efficiency and tissue penetrability of the exosome are improved, a whole-process control system of hydrogel preparation, stem cell culture and exosome purification is constructed, and the stability of the preparation and the yield of the exosome are improved.

The invention discloses a Parabacteroides goldsteinii bacterium and application of a metabolite of the Parabacteroides goldsteinii bacterium in treatment of metabolism-related steatohepatitis and fibrosis related to the metabolism-related steatohepatitis. According to the application disclosed by the invention, firstly, through biological analysis, the fact that Parabacteroides goldsteinii and a metabolite 7-Sulfocholic acid of Parabacteroides goldsteinii are closely related to the progress of MASH related fibrosis is determined; furthermore, functional intervention is implemented in a CDAHFD model, the MASH and the related fibrosis process of the MASH can be remarkably inhibited by supplementing Parabacteroides goldsteinii or 7-Sulfocholic acid, the MASH and the related fibrosis process of the MASH can be relieved, liver fatty degeneration, inflammatory infiltration and collagen deposition can be relieved, and further conversion and application feasibility can be achieved.

The invention discloses an application of a Gnai2 protein inhibitor in preparation of a medicine for treating diabetic nephropathy, and belongs to the technical field of biological medicine, research shows that expression of Gnai2 in a diabetic nephropathy sample is up-regulated and is in positive correlation with a renal injury index, after the Gnai2 gene is knocked out, lipophagy can be promoted, lipid droplet deposition can be reduced, development of diabetic nephropathy can be relieved, and the Gnai2 protein inhibitor can be used for treating diabetic nephropathy. Overexpression of the Gnai2 gene can significantly inhibit lipophagy, promote lipid droplet deposition and aggravate development of diabetic nephropathy. The Gnai2 protein as a drug target can be used for screening and discovering substances for preventing and treating the diabetic nephropathy, and the Gnai2 protein inhibitor has a good application prospect in the aspect of preparing drugs for treating the diabetic nephropathy. According to the invention, the blank of'lipid metabolism disorder 'research in the pathogenesis of diabetic nephropathy is filled, and the normal form transformation of diabetic nephropathy from single sugar control treatment to'lipid metabolism-inflammation / fibrosis' multi-channel precise treatment is promoted.

The invention discloses a collagen injection for tendon repair as well as a preparation method and application thereof, and belongs to the technical field of collagen preparation. The preparation method disclosed by the invention comprises the following steps: by taking a collagen dry product as a raw material, sequentially dissolving, carrying out secondary filtration, separating, preparing fibrotic collagen slurry A, preparing gelatinized collagen slurry B, preparing the solution, homogenizing and filling to prepare the collagen injection capable of being used for tendon repair. The collagen injection provided by the invention shows multiphase transformation during refrigeration and contact with body fluid with body temperature, and does not have the phenomenon of fiber layering in the long-term storage process. The collagen disclosed by the invention is an injection type gel preparation, can be flexibly injected and applied according to the depth and the area of a wound, is beneficial to promoting tissue regeneration and functional repair, and is particularly suitable for tendon injury and other scenes needing collagen to guide cell repair.

The invention provides a self-adaptive multifunctional hydrogel system for cardiac microenvironment regulation after myocardial infarction as well as a preparation method and application of the self-adaptive multifunctional hydrogel system, and belongs to the technical field of biomedical materials. The hydrogel system is hydrogel prepared by taking a micromolecular cross-linking agent, a polymer matrix and drug-loaded microspheres as raw materials. The hydrogel can realize staged response drug release in oxidative stress, inflammation and fibrosis microenvironments after myocardial infarction, has good injectability and self-healing property, and has the functions of ROS removal, nitric oxide release and the like. The invention provides a new strategy for tissue repair after myocardial infarction with multi-channel collaboration and accurate pathological response control.

The application discloses a liposome of a FOXO1 inhibitor AS1842856 and a preparation method and application thereof. The liposome comprises the following raw materials: phospholipid, cholesterol, phospholipid PEG derivative and AS1842856; wherein the proportion of the phospholipid, the cholesterol and the phospholipid PEG derivative (for example, distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000 (DSPE-PEG2000)) is preferably in the range of 10:0.2-2:0.5-5 (w / w); wherein the AS1842856 is wrapped in the liposome. The AS1842856 liposome of the application has excellent physical and chemical properties and has a wide application prospect in the field of fibrosis disease treatment.

The LNTPI is a surgical instrument used to cut through fibrotic and edematous tissue to define the natural tissue plane of dissection. After defining the natural tissue plane, it is designed to move or carefully insinuate tissues along these natural planes without cutting the tissue, so that targeted organs or parts thereof could be viewed and reached during laparoscopic procedures. The following features make the LNTPI unique compared to standard blunt dissectors used in laparoscopy: 1. The tip of the LNTPI is coarse and not smooth. The tip has diagonal, spiral ridges from the sides which are carried onto the tip converging as a single spiral at the center of the tip, creating a pattern resembling that of a screw; 2. The ridges of the LNTPI are comprised of asymmetrical triangular ridges with an acute angle at the apex that may be leaning along with or against the rotation of the spiral; 3. The tip of the LNTPI is made of tungsten carbide metal instead of stainless steel; 4. Dissection can be done in the usual up, down, left, and right motions as standard dissectors; 5. The side of the LNTPI can be used to "peel" tissue by using the ridges on its side combined with a twisting movement. This maneuver cannot be performed using standard dissectors; and 6. The tip of the LNTPI can perform circumferential dissection when used with a twisting movement causing it to engage tissue like a "drill" along the natural tissue plane. The ridges that converge into a single spiral at the tip of the invention appear like a screw and with the proper twisting movement have a similar effect on tissue. Because of the texture, design, and material used for the tip of the LNTPI, it has the following advantages over standard dissectors: The LNTPI can engage tissues more easily even if the tissues are slippery due to the presence of blood or fluids. The LNTPI can be used to engage tissues through a twisting motion which motion allows the tissues to be engaged in a specific manner that defines natural tissue dissection planes. The LNTPI can insinuate / "peel" tissue by using the side spiral ridges in combination with a twisting movement. The LNTPI can perform circumferential dissection by using the tip and the convergence of the spiral ridges at the center of the tip in combination with a twisting movement. The transfer of lateral shear force to the tissue at various angles (45, 90, and 180 degrees) when using the LNTPI is significantly higher whether the motion is by a sweeping motion or twisting of the instrument, allowing it to insinuate better than standard instruments, especially in a wet field. Hand movements needed in insinuating tissue using the LNTPI are different from the usual hand movements when using standard dissection instruments. The hand movements in using LNTPI require less muscular effort and repetitiveness, thus preventing muscle fatigue and repetitive use injury among surgeons. The instrument is reusable, as compared to dissectors that have fabric at the tip, which must be disposed of and replaced once the fabric tip fully absorbs the blood or other fluid in the wet tissue surface.

This invention provides an application of the peptide Nod-T3 in the preparation of drugs for treating lung diseases. The Nod-T3 peptide is derived from human protein and has a significant inhibitory effect on chronic lung inflammation and fibrosis caused by smoking. It can be used to treat COPD and other smoking-related lung diseases. It also has high biocompatibility and low toxicity, and has the potential and development value to become a new type of peptide drug.

The invention provides an application of pentafluridol in preparation of a medicine for inhibiting formation of tumor-associated fibroblasts. Specifically, the invention finds that the pentafluridol can influence the formation process of the tumor microenvironment of the targeted tumor-related fibroblast cells, and the development of solid tumors is effectively inhibited from the source, so that the increase of the tumor volume is inhibited.

Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell are described. The therapeutic compounds are configured to bind CD47 on the surface of a red blood cell and to be subsequently transferred to CD47 on the surface of the target cell, the therapeutic compound ultimately being internalized by the target cell via endocytosis. The target cell may be a cancer cell, a virus-infected cell, or a fibrotic cell.

The invention relates to the technical field of organoid culture, in particular to a pulmonary fibrosis organoid model and a construction method and application thereof. The pulmonary fibrosis organ-like model is obtained by co-culturing lentivirus stably transfected alveolar epithelial cells, human embryonic lung fibroblasts MRC-5 and macrophages. According to the invention, macrophages are innovatively introduced, a ternary co-culture system of lentivirus stably transfected alveolar epithelial cells, human embryonic lung fibroblasts MRC-5 and macrophages is constructed, and a key'epithelial injury-immune infiltration-fibroblast activation 'pathological triangle in a pulmonary fibrosis pathogenesis process can be more comprehensively simulated; the finally obtained pulmonary fibrosis organ-like model provides an efficient tool for pulmonary fibrosis mechanism research and research, development and screening of anti-pulmonary fibrosis drugs.

The application discloses application of a BLM helicase inhibitor in treating myocardial hypertrophy. The application firstly finds that the BLM helicase inhibitor ML216 can significantly inhibit cardiac hypertrophy and myocardial cell fibrosis, thereby providing a new drug for treating myocardial cell hypertrophy diseases in the field, and providing practical experimental evidence and scientific basis for treating myocardial cell hypertrophy diseases, and having a good application prospect in treating myocardial hypertrophy and / or cardiac hypertrophy.

The pharmaceutical composition according to the present invention is used at specific therapeutic regimen and dosage, and can be usefully used for the prevention or treatment of fibrosis.

Crystalline forms of salts of Compound I are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.